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Four children in three unrelated families (one consanguineous) presented with lethargy, hyperlactatemia, and hyperammonemia of un-
explained origin during the neonatal period and early childhood.We identified and validated three differentCA5A alterations, including
a homozygous missense mutation (c.697T>C) in two siblings, a homozygous splice site mutation (c.555G>A) leading to skipping of
exon 4, and a homozygous 4 kb deletion of exon 6. The deleterious nature of the homozygous mutation c.697T>C (p.Ser233Pro)
was demonstrated by reduced enzymatic activity and increased temperature sensitivity. Carbonic anhydrase VA (CA-VA) was absent
in liver in the child with the homozygous exon 6 deletion. The metabolite profiles in the affected individuals fit CA-VA deficiency,
showing evidence of impaired provision of bicarbonate to the four enzymes that participate in key pathways in intermediary meta-
bolism: carbamoylphosphate synthetase 1 (urea cycle), pyruvate carboxylase (anaplerosis, gluconeogenesis), propionyl-CoA carbox-
ylase, and 3-methylcrotonyl-CoA carboxylase (branched chain amino acids catabolism). In the three children who were administered
carglumic acid, hyperammonemia resolved. CA-VA deficiency should therefore be added to urea cycle defects, organic acidurias, and py-
ruvate carboxylase deficiency as a treatable condition in the differential diagnosis of hyperammonemia in the neonate and young child.Hyperammonemia is a medical emergency that requires
immediate and targeted treatment. Correct diagnosis is
therefore essential, but it is challenging given heteroge-
neous etiologies, including genetic (inborn errors of
metabolism), developmental (transient neonatal hyper-
ammonemia), and environmental (infectious hepatitis,
medication) causes.1 We present four children from three
unrelated families with infantile hyperammonemic en-
cephalopathy and hyperlactatemia. The underlying cause
in each of these children was deficiency of carbonic anhy-
drase VA (CA-VA) (CA5A [MIM 114671]), an inborn error of
metabolism broadening the differential diagnosis for
hyperammonemia.
This study was initiated as part of the Treatable Intellec-
tual Disability Endeavor in British Columbia and approved
by the institutional review boards of BC Children’s Hospi-
tal and the University of British Columbia. Parents pro-
vided written informed consent.
In family 1, the female index (II-1 in Figure 1), her
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and deliveries. The index and her male sibling developed
lethargy, tachypnea, hypoglycemia (2.2 and 2.9 mmol/l),
hyperlactatemia (9.8 and 8.8 mmol/l), hypernatremia (Na
152 and 150 mmol/l), and hyperammonemia (780 and
238 mmol/l) with respiratory alkalosis (pH 7.48, pCO2
10.8 mm Hg, HCO3
 10.4 mEq/l; and pH 7.46, pCO2
21 mm Hg, HCO3
 23) within the first days of life. Liver
transaminases, albumin, and clotting factors remained
normal. Urine organic acids demonstrated high lactic,
b-hydroxybutyric, and acetoacetic acid excretion, as well
as increases in carboxylase substrates and related metabo-
lites. Plasma amino acid analysis showed elevations of
glutamine, alanine, and proline and reduction of citrulline
and arginine. Further biochemical test results are shown in
Table 1. Known urea cycle defects and primary causes
of hyperlactatemia were excluded by sequencing and
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CA-VA p.Ser233Pro
Figure 1. Family 1 with p.Ser233Pro
Missense Variant
(A) Pedigree (black fill indicates clinically
affected individuals, II-1 and II-2).
(B) Sanger sequence of CA5A from index
(II-1) and control (wild-type sequence;
WT) subjects; the variant nucleotide posi-
tion and the corresponding codon alter-
ation (p.Ser233Pro) are indicated.
(C) Immunoblot analyses by SDS-PAGE
(ImageJ software) of WT and p.Ser233Pro
(mutant; M) CA-VA protein levels in
COS-7 cell lysates; the molecular weights
(kDa) of protein standards are indicated
on the left. Normal and mutant
(c.697T>C) CA5A cDNAs, including the
full mitochondrial targeting sequences,
were synthesized via the NCBI reference
sequence (NM_001739.1) by Genscript.
The cDNAs were cloned into pUC57 at
XhoI and BglII sites and verified by Sanger
sequencing. Subsequently, the cDNA
inserts were subcloned via the same restric-
tion sites into the pCXN mammalian
expression vector. COS-7 cells (ATCC
CRL-1651) were transfected with wild-type
or mutant CA5A plasmids with Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s protocol, as previously described.8 A b-glucuronidase expression plasmid
was cotransfected as a marker of transfection efficiency.24 COS-7 cells were harvested 48–72 hr after transfection in lysis buffer and
then lysed by sonication on ice.
(D) Thermal stability profiles for WT (red) and p.Ser233Pro mutant (green) CA-VA enzymes. Carbonic anhydrase II (CA2; blue) was used
as a control.synthetase (CPS1 [MIM 608307), and pyruvate carboxylase
(PC [MIM 608786]), as well as measurement of PC and
biotinidase activities in fibroblasts and serum. Hyperam-
monia-hyperornithinemia-homocitrullinuria syndrome
(MIM 238790) and lysinuric protein intolerance (MIM
222710) were excluded on the basis of a normal urine
amino acid profile, and pyruvate dehydrogenase complex
deficiency was excluded on the basis of an elevated lactate:
pyruvate ratio (5.7 mmol/l:0.036 mmol/l ¼ 138 [reference
interval 10–20.7]) in the male sibling. Blue native gel
analysis for respiratory chain complexes I–V was normal.
Molecular analysis of nuclear-encoded ATPase deficiency
(TMEM70 [MIM 612418]) did not reveal disease-causing
mutations. Chromosomalmicroarray analysis (Affymetrix-
Cytoscan HD) was unremarkable, and homozygosity
analysis did not reveal evidence of consanguinity or uni-
parental disomy.
Clinical and metabolic findings normalized in both sib-
lings with the administration of intravenous dextrose and
bicarbonate, as well as enteral carglumic acid (Carbaglu). In
our institution, carglumic acid is used to resolve hyperam-
monemia of unknown origin.2 Brain MRI and MRS on day
5 of life revealed a small periventricular petechial focus
near the trigone of the right lateral ventricle, with a small
lactate peak on spectroscopy in the male sibling; in the fe-
male sibling, both MRI and EEG were unremarkable.
At 2.5 and 3.5 years of age, during intercurrent illness,
the index presented with lethargy, hyperammonemia,
and hyperlactatemia. Hyperammonemia resolved with a
single dose of carglumic acid. She has remained clinically454 The American Journal of Human Genetics 94, 453–461, March 6stable with L-carnitine, vitamin C, coenzyme Q10, and
‘‘sick-day management’’ with high-caloric and lipid-rich
formula during illnesses. At the age of 4.5 years, she ex-
hibited mild axial hypotonia and septal thickening on
cardiac ultrasound. Developmental and behavioral assess-
ment at age 4.5 confirmed average functioning in all do-
mains except for below-average motor coordination (Beery
Buktenica Developmental Test of Visual-Motor Integra-
tion). The male sibling at age 2.3 years had difficulty
engaging in an assessment as a result of heightened activ-
ity and self-directed behavior; scores on Bayley Scales of
Infant and Toddler Development (Third Edition) were
below average. Biochemical profiles and somatic and psy-
chomotor development are unremarkable in the unaf-
fected younger sibling, now 1.5 years of age.
WES was performed for the two affected siblings and
their unaffected parents via the Agilent SureSelect kit and
Illumina HiSeq 2000 (Perkin-Elmer). Rare variants were
assessed for their potential to disrupt protein function
and screened under a series of genetic models—primarily
the Mendelian recessive mode of inheritance given the
rarity of the phenotype and the pattern of inheritance of
most IEMs.
Approximately 99% of the observed variations were
classified as common (Table S1 available online). Eight
rare candidate variants fit the autosomal-recessive model
of homozygous (CA5A, ARSB [MIM 611542], CDKN2B
[MIM 600431], CDKN2A [MIM 600160], OGG1 [MIM
601982]) or compound heterozygous (GRK4 [MIM
137026], SPG11 [MIM 610844], EPHX2 [MIM 132811]), 2014
Table 1. Overview of Biochemical Abnormalities Resulting from CA-VA Deficiency: In Theory and for the Index Cases for Families 1, 2, and 3
Theoretical Possibilities Actual Resultsa
Possible Enzyme Deficiency
Predicted Secondary Biochemical
Abnormalities Metabolite
Family 1 Family 2 Family 3
Female Male Normalb Male Normal Male Normal
carbamoyl phosphate synthetase [ ammonia plasma ammonia (mM) 780* 238* <40 422* <50 258* <40
Y citrulline plasma citrulline (mM) 5* 18 8–47 17 3–36 10–45
Y arginine plasma arginine (mM) 17* NA 32–142 35 17–119 22 12–133
[ glutamine plasma glutamine (mM) 1,051* 1,237* 457–746 2,606* 243–822 571 254–823
N ornithine plasma ornithine (mM) 15* 82 27–207 146 38–272 17 15–200
N orotate urine orotate non-det 1.9 <4.3 2.2 <4.9 0.4 <3
pyruvate carboxylase Y gluconeogenesis (hypoglycemia) serum glucose (mm) 2.2* 2.9* 3.3–7.0 2.9* 3.0–8.0 3.2* 3.5–6.0
serum lactate (mm) 9.1* 8.8* 0.5–2.2 8.1* 1.0–1.8 5.6* 0.6–2.6
plasma alanine (mm) 1,531* 609* 148–475 1,078* 132–455 603* 143–439
redox imbalance ([ lactate & dicarboxylic
acids)
plasma proline (mm) 418* 371* 40–332 625* 78–523 283* 52–298
Y tricyclic acid cycle intermediates
(cataplerosis)
urine lactate 3,737* 4,109* <200 28,000* <456 grossly increased*
urine 3-OH-butryric acid 7,902* 2,657* <21 7,060* <22 grossly increased*
urine aceto-acetic acid 584* 927* non-det þþc grossly increased*
urine fumaric acid 13.8* 38.5* <10 8 <13 moderately increased
urine 2-a-ketoglutaric acid 143* 254.6* <112 300* <267 slightly increased*
urine adipic acid 55* 219.8* <29 340 <25 normal
urine suberic acid 18.6* 48.6* <13 29 <15 normal
urine sebacic acid NA 18.7* <10 NA normal
[ lysine plasma lysine (mm) 87 161 71–272 306 71–272 94 71–272
proprionyl-CoA carboxylase [ 3-OH-propionic acid urine 3-OH-propionic acid 79.38* 54.57* <16 59* <21 normal
[ propionylglycine urine proprionylglycine 1.29* 3.28* non-det 5.6* <2 trace*
[ methylcitrate urine methylcitrate 6.4* non-det non-det normalc trace*
3-methylcrotonyl-CoA carboxylase [ 3methylcrotonylglycine urine 3-methylcrotonylglycine 22.9* non-det <10 17* <5 trace*
[ 3OH-isovaleric acid urine 3-OH-isovaleric acid 40.13* 55.50* <38 327* <55 increased*
All values in urine are expressed as mmol/mmol of creatinine. Abbreviations are as follows: N, normal (within reference range); NA, not available; non-det, nondetectable.
aIn each individual, the value with maximal deviation from normal during crisis is provided. Asterisks (*) indicate abnormal values.
bNormal values differ for each family studied because values were measured in different laboratories.
cQualitative assessment.
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
4
,
4
5
3
–
4
6
1
,
M
a
rch
6
,
2
0
1
4
4
5
5
30
5 
39
 
1  
Ty
r1
64
 
 T
yr
16
7 
H
is
15
5 
Family 1 
Family 3 
Family 2 
Th
r2
35
 
Th
r2
36
 
WT 
Mitochondrial 
translocation 
Zinc 
binding 
Active  
site 
Substrate 
binding 
Del 154-186 
Del 207-258 
p.
Se
r2
33
Pr
o 
Figure 2. Effect of Genetic Variants Identified in CA-VA
Shown is a schematic diagram of the 305 amino acid wild-type
(WT) CA-VA. Residues 1–39 encode a mitochondrial translocation
signal (green). Homology predictions indicate that histidine 155
binds a zinc ion (blue), tyrosines 164 and 167 are active site
residues (black), and threonines 235 and 236 comprise a sub-
strate-binding region (yellow). Shown in red are the deduced
CA-VA variants identified in this study. The index and affected
brother of family 1 has a nonsynonymous Ser to Pro mutation
at residue 233, adjacent to the substrate-binding region. The index
of family 2 has a deletion of residues 154–186 (exon 4), thereby
missing the metal-binding and active-site residues. The index of
family 3 has a deletion of residues 207–258 (exon 6; the sub-
strate-binding region), which results in absent protein.variants in the affected siblings. The final set of rare vari-
ants (mean average frequency < 1%) was assessed for the
potential to disrupt protein function via the Sift and
PolyPhen2 software systems. Of these, only one variant
(c.697T>C; RefSeq accession number NM_001739.1) in
CA5A on chromosome 16 was considered a functional
candidate; this variant was not reported in dbSNP (version
137), NHLBI ESP, or our in-house genome database
(comprising 100 exomes and 10 whole genomes; anno
December 2013). Integrative Genomics Viewer 2.0.34
was used to visualize the read alignment and assess variant
quality prior to Sanger validation. Given the existence of a
related pseudogene,3 the CA5A variant was confirmed by
targeted Sanger sequencing via carefully designed primers
to avoid amplification of the pseudogene sequences; this
was achieved by review of paired-end sequence data and
selection via a BLAST search of appropriate regions with
least similarity, especially close to the 30 end. Affected
siblings are confirmed homozygous, whereas unaffected
parents and the unaffected youngest female are heterozy-
gous carriers (Figures 1A and 1B). This variant corresponds
to a Ser to Pro substitution at position 233 that is predicted456 The American Journal of Human Genetics 94, 453–461, March 6to disrupt structure around the conserved Thr235 residue
that forms part of the substrate-binding region of the
enzyme (Figure 2). Indeed, the p.Ser233 residue is highly
conserved evolutionarily across species and in all 12 active
human carbonic anhydrase isoforms. Studies of human
CA-II have demonstrated that mutations in this hydropho-
bic patch in the active site destabilize the structure around
the substrate-binding region and dramatically reduce the
activity of the mutant CA-II.4
Tissues with CA-VA (liver, kidney, skeletal muscle) were
not available for the affected siblings. Therefore, the effect
of the p.Ser233Pro substitution on CA-VA was character-
ized in cultured mammalian cells (COS-7). A marked
reduction was observed in the steady-state levels of CA-
VA p.Ser233Pro compared with wild-type protein despite
similar transfection efficiencies (Figure 1C). As summa-
rized in Table 2, CA-VA p.Ser233Pro-specific activity in
total cell lysates is reduced to 20% of wild-type protein
activity, whereas activities of the cotransfected marker
enzyme b-glucuronidase were comparable. There was a
negligible change in the activity of mutant enzyme in
the presence of added zinc (22% of WT), suggesting that
both WT and mutant enzymes in COS-7 cells are saturated
with zinc (data not shown). Thermal stability of mutant
recombinant human CA-VA was compared with the WT
CA-VA and recombinant human Carbonic Anhydrase II
as an additional control (Figure 1D). After a 30 min prein-
cubation, themutant enzyme had lost 80% of its activity at
30C and almost all its activity at 40C. By contrast, both
WT CA-VA and human CA-II were much more stable at
30C and 40C, retaining approximately 100% and 70%
residual activity, respectively. In a separate experiment
(Table 3), preincubation of the mutant enzyme at 37C
(normal human body temperature) for 30 min retained
only 5% of mutant enzyme activity, whereas wild-type
protein activity was 80% relative to activity after a 4C
preincubation. The quantity of immune-reactive CA-VA
p.Ser233Pro was demonstrably lower than that of wild-
type CA-VA (37% of wild-type) at 72 hr after transient
transfection of COS-7 cells (data not shown). Similar
temperature-sensitive mutants are associated with disease
in cases of medium chain acyl-coA dehydrogenase defi-
ciency (ACADM [MIM 607008]) and recessively inherited
parkinsonism (PINK1, a putative mitochondrial kinase
[MIM 608309]).5,6
In family 2, a male child (II-1 in Figure 3A) was born
spontaneously at gestational age 36þ2 weeks to noncon-
sanguineous Russian parents. On day 4 of life, he presented
with lethargy, weight loss (15% below birth weight), jaun-
dice, and tachypnea. Initial investigations showed hyper-
ammonemia (316 and 422 mmol/l), hyperlactatemia
(8.1 mmol/l), mild hypoglycaemia (2.9 mmol/l), metabolic
acidosis (pH 7.16, pCO2 13 mm Hg, HCO3
 5 mEq/l), and
ketonuria. Despite fluid resuscitation, sodium bicarbonate
infusion, and antibiotics, the neonate’s clinical and
biochemical status deteriorated; liver transaminases
and synthetic function remained normal. Metabolic, 2014
Table 2. Steady-State Carbonic Anhydrase Activity in COS-7 Cells Cotransfected with Wild-Type and p.Ser233Pro Mutant CA-VA and
b-Glucuronidase
Enzymes
Specific Activity (EU/mg
Cell Protein)
Specific Activity Minus
Vector (EU/mg Cell Protein)
Percent of
WT CA-VA
BGUS Activity
(EU/mg)
Transfection
Efficiency
PCXN vector only 0.28 0.00 0 37.5 1
WT 1.88 1.60 100 7070 188.5
MT 0.60 0.32 20 8550 228
Values represent the average of two transfections; the enzyme activities were determined in duplicate and calculated as enzyme unit (EU) per milligram (mg) of
enzyme protein. The specificity of the assay was verified with the CA-specific inhibitor acetazolamide (500 nM). Abbreviations are as follows: WT, wild-type; MT,
mutant.investigations are shown in Table 1; molecular analysis of
CPS1 and NAGS did not reveal disease-causing mutations.
Carglumic acid and biotin were initiated, along with pro-
tein-free formula and intravenous lipids; 12 hr later, the
metabolic acidosis and hyperammonemia resolved. He
resumed breastfeeding with normal weight gain, ammonia
levels, and urine metabolites. Carglumic acid was stopped
at 4 months of age, and the infant exhibited normal psy-
chomotor development at age 6 months with the use of
sick-day formula during illness.
Sanger sequencing of all seven exons of CA5A in the in-
dex identified a synonymous c.555G>A transition (RefSeq
NM_001739.1) at the final base of exon 4 (Figure 3B).
Given that guanine is the most common nucleotide found
at this end of an exon in vertebrate genes, RT-PCR was un-
dertaken to demonstrate an effect onmRNA splicing.7 RNA
was purified from white blood cells of the index and a
control subject. RT-PCR via primers designed to amplify
exons 2–7 of CA5A generated distinctly different product
sizes (approximately 550 bp and 650 bp, respectively;
Figure 3B). Sanger sequencing of the ~550 bp band re-
vealed an in-frame deletion of exon 4 from the index
RNA (Figure 3C). We cannot exclude the presence of other
transcripts in vivo, which were missed because of the
limited sensitivity of the assay combined with low CA5A
expression in white blood cells. Alternatively, this single
transcript may be explained by preferential formation
during the transcription/splicing processes. Homology
with carbonic anhydrase isoforms identifies three critical
residues in the deleted CA-VA transcript (residues 154–
185): His155, which binds to a catalytically essential zinc
molecule, and Tyr164 and Tyr167, which form part of
the active site of the CA-VA enzyme.8 Thus, this deletion
is predicted to significantly impair CA-VA enzyme activity,
if not lead to protein misfolding and degradation.
In family 3, a male child (II-5 in Figure 4A) was born at
term by Caesarian section (because of placenta previa) as
the youngest of five children to first-cousin consanguin-
eous Pakistani parents. At 13 months of age, after unre-
markable development, he presented with a 1-day history
of visual unresponsiveness. At admission, he was encepha-
lopathic with hyperammonemia (258 mmol/l) and hyper-
lactatemia (4.9 mmol/l), with a compensated metabolic
acidosis (pH 7.43, pCO2 24.8 mm Hg, HCO3
 14 mEq/l).
His encephalopathy improved after 48 hr of intravenousThe Amefluids and antibiotics administered for presumed me-
ningo-encephalitis (cultures were negative). At the age of
16 months, he had a similar crisis; there were no signs of
liver injury. Further metabolic investigations are shown
in Table 1. Sodium benzoate and L-arginine were initiated
with improvement after 48 hr, and he was discharged on a
protein-restricted diet. Urea cycle defects (OTC [MIM
311250], CPS1 [MIM 237300], NAGS [MIM 237310] defi-
ciencies) and PC (MIM 266150), citrin (MIM 605814),
and biotinidase (MIM 253260) deficiencies were excluded
by molecular or enzymatic analyses. After these two crises,
he has demonstrated good developmental progress with
only minor learning difficulties (no formal testing was
available). He continues to have infrequent episodes of
vomiting and ketoacidosis without hyperammonemia or
lactic acidosis; the frequency of these episodes has not
increased since the withdrawal of sodium benzoate and
arginine therapy at the age of 7 years.
Sanger sequencing of the CA5A exons for the index
revealed a deletion of 4 kb encompassing exon 6
(Figure 4B). Relative copy number was assessed in the
family via qPCR of exon 6 sequence, confirming the homo-
zygous deletion in the two siblings and heterozygosity in
the parents (Figure S1). Absence of CA-VA protein was
confirmed by immunoblot in existing liver biopsy tissue
(Figure 4C). Limited information is available on the
neonatal and early childhood course in his four older
siblings; parents reported no major health problems and
normal learning ability. The oldest brother (II-2 in Figure 4)
is homozygous for the CA5A deletion but declined further
evaluation at age 17. Neonatal or childhood insults and a
possible mild presentation cannot be excluded because of
limited history. A benign clinical course after early child-
hood is consistent with the index cases of each of the three
families after initial metabolic decompensations. The
condition may exhibit intrafamilial variability of the
phenotype, as reported for other inborn errors of meta-
bolism.9,10
CA-VA deficiency is a human inborn error of metabolism
presenting with hyperammonemic encephalopathy in
early life. Initial evidence of causality for the identified
CA5A alterations is provided by their similar biochemical
phenotypes during metabolic crises. Findings are con-
sistent with dysfunction of all four enzymes to which
CA-VA provides bicarbonate as substrate in mitochondriarican Journal of Human Genetics 94, 453–461, March 6, 2014 457
Table 3. CA-VA Wild-Type and p.Ser233Pro Mutant Enzyme
Activities in COS-7 Cell Lysates, before and after Incubation at
Human Body Temperature
Enzyme
EU/mg Cell Protein
before Heating
EU/mg Cell Protein after
Heating (30 min at 37C)
WT 1.02 (100%) 1.25 (100%)
MT 0.15 (14.7%) 0.07 (5.4%)
The enzyme activities were determined in duplicate and calculated as enzyme
unit (EU) per milligram (mg) of enzyme protein. Incubation was at 37C for
30 min. Abbreviations are as follows: WT, wild-type; MT, mutant.(CPS1 and three biotin-dependent carboxylases: pro-
pionyl-CoA [PCC], 3-methylcrotonyl-CoA [3MCC], and
pyruvate carboxylase [PC]).
The carbonic anhydrase family of zinc-containing
metallo-enzymes all catalyze the reversible conver-
sion of carbon dioxide to bicarbonate (CO2 þ H2O 4
HCO3
 þ Hþ). Mitochondria are impermeable to HCO3,
and thus the two intramitochondrial carbonic anhydrases
(CA-VA and CA-VB) are pivotal in providing HCO3
 for
multiple mitochondrial enzymes that catalyze the forma-
tion of essential metabolites of intermediary metabolism
in the urea and Krebs cycles (Figure 5).11,12
These include CPS1, which catalyzes the synthesis of
carbamoylphosphate from ammonia and bicarbonate, a
rate-limiting step in the conversion of waste nitrogen
into urea, and pyruvate carboxylase (PC), which stands at
the interface between glycolysis and the Krebs cycle, facil-
itating the production of oxaloacetate from pyruvate, the
former being a major anaplerotic substrate essential for
the maintenance of the Krebs cycle.13 Primary PC defi-
ciency is biochemically characterized by lactic acidosis,458 The American Journal of Human Genetics 94, 453–461, March 6hyperammonemia, and hypoglycemia, as was observed
in our CA-VA-deficient individuals with presumed second-
ary PC deficiency leading to hypoglycemia through
impaired gluconeogenesis.14
CA-VA deficiency provides the unique opportunity to
study the opposite consequences of CPS1 deficiency
(hyperammonemia, elevated glutamine, and decreased
citrulline and other amino acids distal to the block) and
PC deficiency (hyperammonemia, normal to decreased
glutamine, increased citrulline and lysine). Given that
glutamine was elevated in three of the four affected indi-
viduals and that the citrulline was low to normal in all, it
appears that an impaired urea cycle, rather than deficient
glutamate, was the major cause of hyperammonemia.
Combined with the normal lysine levels and relatively
mild elevations of 2-a-ketoglutaric acid and other Krebs
cycle intermediates, the biochemical profiles in our
CA-VA deficiency individuals support a predominant effect
of (secondary) CPS1 versus PC deficiency.
The observed moderate increase of urinary 3-OH propi-
onic acid, propionyl glycine, and methylcitrate along
with traces of 3-methylcrotonylglycine are consistent
with the expected reduced activities of PCC and 3MCC
in CA-VA deficiency. Although biotinidase and holocar-
boxylase synthetase (HCS [MIM 253270]) deficiencies
share the metabolite profiles of secondary PC, PCC, and
3MCC deficiencies, there are three major differences
relative to primary CA-VA deficiency: (1) the significantly
higher level of PCC and 3MCC metabolites in (even well-
controlled) individuals with the two former disorders
compared to those with CA-VA deficiency during meta-
bolic decompensation; (2) the presence of CPS1 deficiency
as (likely) major cause of hyperammonemia in CA-VAFigure 3. Family 2 with Exon 4 Splice
Deletion
(A) Pedigree (black fill indicates clinically
affected individual).
(B) Sanger sequencing of RT-PCR products
generated in (B) with exons denoted by
colors. Top: The CA5A structure (not to
scale) and a schematic of the observed
CA5A transcripts produced in a control
subject and the index. Bottom: Sanger
sequence of transcripts at exon 4 boundary
in a control subject (þ/þ) and the index
(/), along with WT CA5A cDNA
sequence, color-coded as in the top panel.
(C) RT-PCR of CA5A mRNA from white
blood cells (WBCs) or cultured liver cells
(HepG2). Arrows indicate the products of
differing size amplified from control
subject (WT sequence) and index (II-1)
WBCs. As controls, reverse transcriptase
was omitted from the reaction (no RT)
and a control gene (b-actin) was amplified
in separate lane on a different cell type
(denoted by the line).
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AB
C Figure 4. Family 3 with Exon 6 Deletion
(A) Pedigree (black fill indicates clinically
affected individual, II-5).
(B) Top: Schematic representation of the
4,078 bp deletion that encompasses exon
6 of CA5A. Bottom: Sanger sequencing of
PCR products generated from genomic
DNA of the index (II-5) with a 21 bp
repeated sequence (gray) at the breakpoint
found in both intron 5 (green) and intron
6 (blue).
(C) Immunoblot analyses of control sub-
ject (WT) and index (II-5) liver homoge-
nates. Samples were probed for CA-VA,25
cytochrome c (Cyto-c), carbonic anhy-
drase XIV (CA 14),26 and carbonic anhy-
drase II (CA 2)27 via specific antibodies.deficiency; and (3) the presence of acetyl-CoA carboxylase
deficiency (MIM 613933) in HCS and biotinidase defi-
ciency.15,16 Our CA-VA-deficient individuals exhibited
normal levels of free fatty acids and of total and free
carnitine, as well as normal acylcarnitine profiles (data
not shown), mostly probably as a result of the activity of
the cytosolic acetyl-CoA carboxylase 2 isoform that is
not affected by impaired provision of mitochondrial
HCO3
.17
Although not approved for this indication, carglumic
acid may be of benefit as synthetic treatment of partial
CPS1 deficiency through its known ability to enhance the
activity of this enzyme.2 This could increase production
of carbamoyl phosphate even at HCO3
 levels below the
Km for the enzyme. Although the hyperammonemia re-
sulted from a reduction of substrate to CPS1, rather than a
primary CPS1 deficiency, three individuals (families 1 and
2) showedagood response to carglumic acid (normalization
of ammonia and for the female of family 1, a mild increase
of citrulline), consistent with the suggestion that enhanced
CPS1 activity can partially compensate for reduced HCO3

resulting fromCA-VAdeficiency. This hypothesis should be
tested in the Car5A-null mouse model (Car5Adl1Sws),18
especially given the high cost of this medication and
uncontrolled circumstances in which these children were
managed with multiple therapeutic modalities.
Newborn screening profiles (Tandem MS/MS), specif-
ically C3 and C5OH levels, were unremarkable in all four
cases, probably because of the relatively mild biochemical
profile for the carboxylase-related metabolites along with
the low sensitivity of acylcarnitine analyses compared to
urine organic acids. Furthermore, outside of acute events,
biochemical parameters remained normal in all affectedThe American Journal of Humanchildren except for mildly elevated
blood lactate and/or ketonuria. We
propose several explanations for the
relatively benign clinical course in
these individuals and lack of apparent
phenotype in the oldest male sibling
in family 3. First, overlapping func-tion of CA-VB may help prevent deleterious sequelae of
reduced CA-VA activity.19 In the mouse, Car5A is mainly
localized in liver and its deficiency results in profound hy-
perammonemia. Car5B, though almost undetectable in
liver, is predominant in mitochondria of many other tis-
sues. Nonetheless, Car5B deficiency alone has no obvious
phenotype. However, when superimposed on Car5A defi-
ciency in the doubly deficient mouse (Car5Adl1Sws/
Car5Bdl1Sws), Car5B deficiency aggravated the hyperam-
monemia and hypoglycemia and shortened survival.18
Thus, Car5B does contribute to handling the metabolic
load, though its action is evident only in the absence of
Car5A. Second, although carbonic anhydrases accelerate
the conversion of CO2 to HCO3
 by 1,000-fold or greater,
some bicarbonate is produced via the nonenzymatic reac-
tion, even in the absence of carbonic anhydrases.20 Suffi-
ciency for the product of this limited nonenzymatic source
of bicarbonate may differ for the four different bicarbon-
ate-requiring enzymes depending on their individual Kms.
Thus, CA-VA deficiency should be considered among
urea cycle defects, organic acidurias, and PC deficiency in
the differential diagnosis for hyperammonemia and hyper-
lactatemia in the neonate and young child. Whereas many
of the biochemical markers are nonspecific, some metabo-
lites such as propionylglycine and 3-methylcrotonylgly-
cine are more specific for deficiencies of PCC and 3MCC
deficiencies that occur secondary to CA-VA deficiency.
However, the increase in these metabolites is subtle
compared with individuals who have a primary defect of
these enzymes. Furthermore, these abnormalities may be
present only during symptomatic episodes. Therefore,
diagnostic molecular analysis of CA5A should be consid-
ered in persons with suggestive biochemical findings.Genetics 94, 453–461, March 6, 2014 459
Figure 5. Biochemical Pathways
Affected by CA-VA Deficiency
CA-VA deficiency is indicated by the
horizontal red bar (bottom right). Dotted
lines link CA-VA-mediated bicarbonate
production and intramitochondrial
donation to the bicarbonate-dependent
carboxylases; the affected enzyme defi-
ciencies are denoted with red circles.
Enzymes: CPS1, carbamoylphosphate
synthetase I; PC, pyruvate carboxylase;
PCC, propionyl CoA carboxylase; 3MCC,
3-methylcrotonyl CoA carboxylase.
Metabolites: SUC, succinyl CoA; aKG,
a-ketoglutarate; OAA, oxaloacetate; Glu,
glutamate; Gln, glutamine; Sac, saccharo-
pine; Lys, lysine; ASP, aspartate; PEP, phos-
phoenolpyruvate; PYR, pyruvate; LAC,
lactate; AcCoA, acetyl CoA; AS, arginino-
succinate; 3MGCoA, 3-methylglutaconyl
CoA; 3MCCoA, 3-methylcrotonyl CoA.CA-VA deficiency expands the list of treatable inborn
errors of metabolism potentially causing intellectual
disability.21 Effective therapy in the affected individuals
comprised (1) preventive sick-day management during
intercurrent illnesses, including a high-caloric, lipid-rich
formula restricted in protein but normal in carbohydrates;
and possibly (2) carglumic acid to enhance the activity of
the first step in the urea cycle as a treatment for the
hyperammonemia.
Other experimental therapies deserving exploration
include oral zinc supplementation (a CA-VA cofactor
that may increase residual activity in persons with muta-
tions outside the zinc-binding site) and interventions to
enhance or replace anaplerosis to alleviate metabolic
symptoms of PC dysfunction, such as the administration
of aspartate and citrate (but not triheptanoin, given
the secondary PCC deficiency22), as demonstrated by
improved growth and survival in CA-VA-null mice
receiving citrate water.18,23Supplemental Data
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